State Drug Price Transparency Laws

Petauri PACT Executive Briefings - 3-Minute Market Insights

Innhold levert av The Kinetix Group, Powered by Petauri, The Kinetix Group, and Powered by Petauri. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av The Kinetix Group, Powered by Petauri, The Kinetix Group, and Powered by Petauri eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

7M ago 2:46

MP3•Episoder hjem

Send us a text

Since 2016, 13 states have passed Drug Price Transparency Laws focused on enabling state policymakers to understand opaque drug pricing and payment systems to formulate policy solutions to high prices, while also creating the data infrastructure to realize those policy solutions.

Most of these state programs require reporting from manufacturers when they increase the Wholesale Acquisition Cost (WAC) of a drug above a certain threshold or if they introduce a drug with a high launch price.

Since 2020, 8 states have enacted Prescription Drug Affordability Boards often referred to as P-DABs, entities with the authority to review high cost drugs and in some states set an upper payment limit to ensure no one pays more than that amount in the state.
You can download the full Executive Briefing at: https://tkgpact.com/executive-briefings/

Or, feel free to email us at Insights@thekinetixgroup.com

61 episoder

#Fitness #Medicine #The Kinetix Group #Healthcare #Pharma #Voice #Triple Aim #Biotech #Health Management #Science #Alternative Health #Biology #Insight